Osteoporosis: A Therapeutic Update Patricia A. Mackey, FNP-BC, BC-ADM, Michael D. Whitaker, MD, FRCPC  The Journal for Nurse Practitioners  Volume 11, Issue 10, Pages 1011-1017 (November 2015) DOI: 10.1016/j.nurpra.2015.08.010 Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 1 Bone remodeling cycle. Points of therapeutic intervention include preventing osteoclast function (Antiresorptive Rx) or enhancing osteoblast action (Anabolic Rx). The Journal for Nurse Practitioners 2015 11, 1011-1017DOI: (10.1016/j.nurpra.2015.08.010) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 2 Bone density loss over time in postmenopausal women. The expected effect of antiresorptive therapy (Rx) is to stabilize bone density as inhibition of resorption ultimately leads to inhibition of formation. Formation-stimulating therapy (anabolic) should lead to further increases in bone density. Initiation of therapy sooner rather than later should predictably help prevent further loss and decrease the risk of fracture. The Journal for Nurse Practitioners 2015 11, 1011-1017DOI: (10.1016/j.nurpra.2015.08.010) Copyright © 2015 Elsevier Inc. Terms and Conditions